Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC
NCT07742332Phase 2
Key facts
- Status
- Recruiting
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Countries
- 1
- Drugs
- Fumetinib
- Conditions
- non-small cell lung cancer (NSCLC)
01
Overview
Phase 2, randomised trial of Fumetinib in non-small cell lung cancer (NSCLC) (2 arms). Primary endpoint: Progression-free survival up to 60 months. Started Nov 2025; status: recruiting.
02
Design
2 arms- Study design
- Randomized
Fumetinib + Chemotherapy
Fumetinib combined platinum-based double chemotherapy
Concurrent Radiochemotherapy
Concurrent Radiochemotherapy
03
Who it enrols
Adults with stage II-IIIA NSCLC with EGFR sensitive mutations, no prior systemic anti-cancer treatment, ECOG PS 0-1, and adequate organ function.
04
Endpoints
Primary
Progression-free survival
Secondary
Major pathologic response
Beyond the preview
Go deeper on NCT07742332.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07742332.